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This study aimed to elucidate the protective potential of angiostatin in inﬂamed endothelial cells in
culture. We assessed the effect of angiostatin on the expression of ICAM-1 and eNOS. Angiostatin pre-
vented IL-1b-induced down-regulation of eNOS expression, but produced no signiﬁcant changes on IL-
1b-induced up-regulation of ICAM-1. We then explored the effect of angiostatin on IL-1b-mediated in-
ﬂammatory signaling and found that angiostatin inhibited IL-1b-mediated nuclear translocation of NF-
kB. Thus, our results suggest that angiostatin prevents IL-1b-induced down-regulation of eNOS expres-
sion via inhibition of the NF-kB cascade; this may be the anti-inﬂammatory mechanism of angiostatin.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Angiostatin, the N-terminal fragment of plasminogen consisting
of a kringle (K) domain, was originally puriﬁed as a potent angio-
genic inhibitor in mice with Lewis lung carcinoma (1). It speciﬁcally
inhibits proliferation and induces apoptosis in vascular endothelial
cells, thus inhibiting tumor growth. The anti-inﬂammatory prop-
erties of angiostatin were recently reported. Angiostatin improves
early-stage atherosclerosis in apolipoprotein (Apo)-E deﬁcientmice
and limits chronic kidney injury in streptozotocin-induced diabetic
rats via anti-inﬂammatory mechanisms (2). The local angiostatin
levels are dramatically decreased in the kidney of diabetic rats and
adenovirus-mediated over-expression of angiostatin attenuated
the diabetic nephropathy (3). Previous report indicated that
angiostatin efﬁciently inhibited the TGF-b-induced MCP-1 and
ﬁbronectin expression in mesangial cells (3). However, the detailed
mechanisms of anti-inﬂammatory effects of angiostatin in endo-
thelial cells were not clear.
The endothelium has emerged as a key regulator of vascular
homeostasis and inﬂammation (4). The endothelial inﬂammatory
response is of critical importance in diseases such as chronic
venous insufﬁciency, thrombosis, and atherosclerosis. Endothelialþ81 19 698 1833.
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d/4.0/).activation and dysfunction are considered primary disease states
(4,5). Endothelial activation is deﬁned by the expression of cell-
surface adhesion molecules such as E-selectin, ICAM-1, and
VCAM-1, and facilitates recruitment of circulating leukocytes to the
vessel wall. Endothelial dysfunction is deﬁned as the reduced
synthesis and release of endothelium-derived nitric oxide (NO) (5).
NO production is catalyzed by endothelial nitric oxide synthase
(eNOS) to maintain the integrity of endothelial cells. NO blocks
endothelial cell activation and injury induced by cytokines, has
antithrombogenic properties, and promotes vasodilation (6).
Impaired NO generation caused by inhibition of eNOS is thought to
cause endothelial dysfunction.
Inﬂammatory cytokines, including IL-1b, IL-6 and TNFa are
strong mediators for the development of diabetes (7,8). These cy-
tokines are related to subsequent expression of chemotactic factors
and adhesion molecules in endothelial cells. In this study, we
investigated the anti-inﬂammatory effects of angiostatin (Kl-4) on
IL-1b-mediated endothelial activation and dysfunction in human
umbilical vein endothelial cells (HUVECs), simulating blood vessel
inﬂammation for diabetes. Angiostatin suppressed IL-1b-mediated
down-regulation of eNOS by inhibiting translocation of NF-kB to
the nucleus. These results provide a partial characterization of the
molecular mechanism that underlies the anti-inﬂammatory prop-
erties of angiostatin.nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Fig. 1. Effect of IL-1b on expression of eNOS and ICAM-1 in HUVECs. HUVECs were
treated with IL-1b for 24 h, and the lysates of HUVECs were analyzed by Western
blotting with antibodies against eNOS, ICAM-1, and b-actin. A representative blot is
shown. Protein levels of eNOS and ICAM-1 were normalized to those of b-actin and
expressed relative to IL-1b-negative control (1.0). Data are expressed as mean ± SD of
three independent experiments. *P < 0.05 versus IL-1b negative control.
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Scientiﬁc, Rockford, IL, USA); human recombinant IL-1b (PeproTech,
Rocky Hill, NJ, USA). The following primary antibodies were used
for Western blot analysis: anti-eNOS (BD, Biosciences, San Jose, CA,
USA); anti-ICAM-1 or anti-histone H1 (Santa Cruz Biotech. Santa
Cruz, CA, USA); anti-b-actin (SigmaeAldrich); anti-NF-kB p65 (Cell
Signaling Technology, Boston, MA, USA). HUVECs were purchased
from Cell Applications (San Diego, CA, USA) and cultured in growth
medium at 37 C; cells were used at the ﬁfth or sixth passage for
experiments. HUVECs were cultured for 24 h in the presence or
absence of IL-1b (from 0.1 to 10 ng/mL); angiostatin was added
30 min prior to the addition of IL-1b.
Method of Western blot analysis was performed as descried (9).
To evaluate the eNOS and ICAM-1 mRNA expression, we performed
quantitative real-time PCR using a 7900HT Fast Real-Time PCR
system (Applied Biosystems, Foster City, CA) with SYBR green
Master Mix (Life Technologies). For ampliﬁcation, the following
primer pairs were used: eNOS (50-primer 50-accctcaccgctacaacatc-
30, 30-primer 50-gctcattctccaggtgcttc-30), ICAM-1 (50-primer 50-
ggctggagctgtttgagaac-30, 30-primer 50-actgtggggttcaacctctg-30) and
GAPDH (50-primer 50-gagtcaacggatttggtcgt-30, 30-primer 50-
ttgattttggagggatctcg-30). The housekeeping gene GAPDH was used
as an internal standard. Relative quantitation of eNOS mRNA levels
was performed by the comparative CT method. Statistical analysis
was performed by one-way analysis of variance (ANOVA) followed
by Dunnett's test for multiple comparisons using GraphPad PRISM
5 (GraphPad Software, San Diego, CA, USA). Linear trend tests were
performed by post-test analysis with GraphPad PRISM 5. Data are
reported as mean ± SD.
Nuclear translocation of NF-kB p65 was observed by immuno-
cytochemistry and Western blot analysis with nuclear extracts. For
immunocytochemical analysis, cells were ﬁxed with 4% para-
formaldehyde and incubated in PBS() containing 3% BSA with an
antibody against NF-kB p65 (1/100) at 4 C overnight. After
washing, the cells were stained with TRITC-conjugated anti-mouse
antibody (1/400) and Hoechst 33258 (Dojindo Laboratories,
Kumamoto) and examined by FV1000 confocal microscopy
(Olympus, Tokyo). To prepare nuclear extract, HUVECs were pre-
incubated with angiostatin (10 mg/mL) for 30 min, and 1 ng/mL IL-
1b was added in 100-mm dishes for 60 min. Nuclear extracts were
prepared following the protocol of Abmayr et al. (10). All experi-
ments were performed independently at least three times.
In preliminary examination, HUVECs were treated with high
glucose (30 mM glucose), IL-1b (10 ng/mL) or TNFa (10 ng/mL),
simulating for diabetes, with or without angiostatin and expression
of eNOS and ICAM-1 were measured by Western blotting. Since IL-
1b most affected the expression of eNOS with angiostatin (Y. Ka-
wasaki et al., unpublished data), we used IL-1b in the following
experiments. HUVECs were treated with various concentrations of
IL-1b (from 0.1 to 10 ng/mL) for 24 h, and eNOS and ICAM-1 protein
levels were measured by Western blotting. IL-1b induced marked
down-regulation of eNOS and up-regulation of ICAM-1 in a dose-
dependent manner as previously described (Fig. 1) (11). Under
the same conditions, iNOS expression was not detected. We
investigated the effects of angiostatin on the IL-1b-induced
decrease in eNOS and increase of ICAM-1. The IL-1b-induced
decrease of eNOS was restored by angiostatin in a dose-dependent
manner (Fig. 2A); however, the IL-1b-induced increase in ICAM-1
was not affected. Consistent with the Western blot data, tran-
script levels of eNOS were signiﬁcantly down-regulated by IL-1b
and were restored by angiostatin in a dose-dependent manner
(Fig. 2B).
Next, we investigated effects of angiostatin on IL-1b-mediated
inﬂammatory signaling. Although we examined activation of the
p38 MAPK and JNK cascades, both of which regulate eNOStranscription, angiostatin did not affect the phosphorylation of p38
MAPK and JNK induced by IL-1b (Y. Kawasaki et al., unpublished
data). Another inﬂammatory signals induced eNOS transcriptional
regulator is NF-kB (12). To determine whether angiostatin affects
the nuclear translocation of NF-kB, HUVECs were treatedwith IL-1b
for 60 min in the presence or absence of angiostatin, followed by
immunocytochemistry with anti-NF-kB p65 antibody. IL-1b
induced predominantly nuclear translocation of NF-kB at 60 min
(Fig. 3A). In contrast, pre-treatment with angiostatin signiﬁcantly
attenuated NF-kB p65 nuclear translocation by IL-1b (Fig. 3B).
Furthermore, we examined NF-kB levels in nuclear extracts isolated
from IL-1b-induced HUVECs and found that nuclear accumulation
of NF-kB in IL-1b-treated cells was reduced by angiostatin (Fig. 3C,
D). These results suggest angiostatin inhibits IL-1b-induced down-
regulation of eNOS by inhibiting nuclear translocation of NF-kB.
It is well known that angiostatin has anti-angiogenic properties
such as inhibition of proliferation andmigration in endothelial cells.
Chang et al. demonstrated that angiostatin K1-5 directly reduced
TNF-a-induced expression of ICAM-1 and VCAM-1 by repression of
IkB degradation, suggesting that angiostatin inhibits endothelial
activation (13). On the other hand, the function of angiostatin
against endothelial dysfunction has not been studied so far. Since
the present study showed that angiostatin inhibited IL-1b-induced
endothelial dysfunction, angiostatin probably served as an anti-
inﬂammatory factor through the inhibition of both endothelial
activation and dysfunction. Enhancement of NO availability by
Fig. 2. Effect of angiostatin on IL-1b-induced eNOS and ICAM-1 expression in HUVECs. HUVECs were preincubated with angiostatin for 30 min, following which 1 ng/mL IL-1b was
added to the cells and incubated for 24 h. A) eNOS, ICAM-1, and b-actin were detected by Western blotting. A representative blot is shown. Protein levels of eNOS and ICAM-1 were
normalized to those of b-actin and expressed relative to IL-1b and angiostatin-negative control (1.0). Data are expressed as mean ± SD of three independent experiments. *P < 0.05
versus presence of IL-1b and absence of angiostatin. B) eNOS and ICAM-1 transcript levels were measured by real-time PCR, normalized to those of GAPDH, and expressed relative to
IL-1b and angiostatin-negative control (1.0). Data are expressed as mean ± SD of three independent experiments. *P < 0.05 versus presence of IL-1b and absence of angiostatin. (P for
linear trend < 0.001, presence of IL-1b and absence of angiostatin versus presence of angiostatin and IL-1b).
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striction, inhibition of ﬁbrosis and platelet aggregation. It has been
thought that a renal protection effect with angiostatin for diabetic
nephropathy was anti-inﬂammatory action of mesangial cells (3).
The inhibitory effect of endothelial dysfunction by angiostatin
might contribute to improvement to diabetic nephropathy.
We showed that angiostatin inhibited inﬂammatory cytokine-
induced-NF-kB signaling; however, angiostatin did not affect the
IL-1b-induced increase in ICAM-1. Plasminogen is cleaved byMMP-
2, -7, -9, elastase, or cathepsin D, and generates various kringle-
containing fragments such as angiostatin K1-3 (38 kDa), K1-4
(50 kDa), and K1-5 (56 kDa) (14). Each form of angiostatin has adifferent antiproliferative or anti-inﬂammation effect. Angiostatin
K4 is the most potent inhibitor of endothelial cell migration,
whereas K1-3 has an antiproliferative effect on endothelial cells.
Interestingly, angiostatin K1-5 exhibits a greater anti-inﬂammatory
and anti-angiogenesis effect than do K1-3 and K1-4 in Apo-E
deﬁcient mice or in a mouse model of corneal neovascularization
(15). We observed no effect of angiostatin on IL-1b-induced
expression of ICAM-1, perhaps because the HUVECs in this exper-
iment were treated with angiostatin K1-4.
We indicated that angiostatin inhibited IL-1b-induced nuclear
translocation of NF-kB. This nuclear translocation of NF-kB
decreased to approximately 50% of angiostatin after IL-1b
Fig. 3. Effect of angiostatin on IL-1b-induced NF-kB nuclear translocation in HUVECs. A) HUVECs were incubated in growth factor-free medium (basal medium) for 24 h. Cells were
preincubated with 10 mg/mL angiostatin for 30 min, following which 1 ng/mL IL-1b was added to the cells and incubated for 60 min. The localization of NF-kB p65 was detected by
immunocytochemistry with anti-NF-kB p65 antibody and TRITC-labeled goat-anti-rabbit antibody. Nuclei were stained with Hoechst 33258. NF-kB nuclear translocation is indi-
cated by arrowheads. Scale bars indicate 20 mm. B) Localization of NF-kB in the cytoplasm or nuclei was quantiﬁed. Data are expressed as % of NF-kB localization ±SD of three
independent experiments. *P < 0.05 versus IL-1b negative control. C) HUVECs were preincubated with 10 mg/mL angiostatin for 30 min, following which 1 ng/mL IL-1bwas added to
the cells and incubated for 60 min. Nuclear extracts were prepared and Western blotting was performed with anti-NF-kB p65 and anti-histone H1 antibody. Expression of histone
H1 served as an internal control. D) Protein levels of NF-kB in the nuclei were measured. NF-kB was normalized to those of Histone H1 and expressed relative to presence of IL-1b
(1.0). Data are expressed as mean ± SD of three independent experiments. *P < 0.05.
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induced by proinﬂammatory cytokines down-regulates eNOS (12).
Our results suggest that this is mainly due to inhibition of the NF-kB
cascade by angiostatin. Although angiostatin did not completely
restore IL-1b-induced down-regulation of eNOS transcript and
protein levels, the MAPKs may partially mediate the suppression of
eNOS by IL-1b. We did not explore the angiostatin receptor that
mediates its anti-inﬂammatory action. Further studies are needed
to characterize the precise site of angiostatin activity.
In this study, angiostatin K1-4 prevented endothelial dysfunc-
tion but not endothelial activation. This ﬁnding provides a partial
deﬁnition of the mechanism underlying the anti-inﬂammatory
properties of angiostatin.Conﬂict of interest
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